Study identification

PURI

https://redirect.ema.europa.eu/resource/33911

EU PAS number

EUPAS20668

Study ID

33911

Official title and acronym

Prospective Case-Control Safety Study of Bronchitol (inhaled mannitol) in Patients with Cystic Fibrosis from the UK CF Registry

DARWIN EU® study

No

Study countries

United Kingdom

Study description

Post-authorisation safety study is being conducted pursuant to an obligation imposed by the EMA as a condition of the granting of a marketing authorisation for Bronchitol (mannitol) to confirm the safety profile of Bronchitol, identify, characterise and/or quantify any emergent safety issues, and measure the effectiveness of agreed risk management strategies.

Study status

Finalised
Research institutions and networks

Institutions

Cystic Fibrosis Trust
United Kingdom
First published:
01/02/2024
InstitutionNot-for-profit

Contact details

Siobhán Carr

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Pharmaxis Ltd
Study protocol
Initial protocol
English (296.67 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 2 (specific obligation of marketing authorisation)